Biogen Profit Surges, Tecfidera Disappoint
October 22, 2014 at 08:56 AM EDT
Sales of Biogen Idec Inc's big-selling new oral multiple sclerosis drug Tecfidera fell short of lofty Wall Street estimates for the first time and its shares fell nearly 3 percent, even as the company reported higher-than-expected third-quarter profit and raised its full-year earnings forecast.
